- ISIN
- US89377M1099
- CUSIP
- 89377M109
- Sector
- Healthcare
- Industry
- Medical Devices
- IPO Date
- May 2, 2019
Highlights
- Market Cap
- $2.73B
- Enterprise Value
- $3.11B
- EPS (TTM)
- $4.34
- PE Ratio
- 17.40
- PEG Ratio
- 0.04
- Total Revenue (TTM)
- $635.89M
- Gross Profit (TTM)
- $375.74M
- EBITDA (TTM)
- $125.51M
- Year Range
- $60.11 - $156.00
- Target Price
- $144.75
- ROA (TTM)
- 11.98%
- ROE (TTM)
- 34.80%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
TMDX Performance Chart
TransMedics Group, Inc. (TMDX) is down 37.9% since the beginning of the year. At $76 per share, TMDX is trading 51.6% below its 52-week high of $156. Investors who bought $1,000 worth of TMDX shares 5 years ago would now be looking at an investment worth $2,482.
Loading charts...
Returns By Period
TransMedics Group, Inc. (TMDX) has returned -37.93% so far this year and -38.89% over the past 12 months.
TransMedics Group, Inc.
- 1D
- -4.16%
- 1M
- 9.54%
- YTD
- -37.93%
- 6M
- -41.62%
- 1Y
- -38.89%
- 3Y*
- -1.94%
- 5Y*
- 19.94%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
TMDX Monthly Returns History
Based on dividend-adjusted daily data since May 2, 2019, TMDX's average daily return is +0.17%, while the average monthly return is +4.20%. At this rate, an investment would double in approximately 1.4 years.
Historically, 56% of months were positive and 44% were negative. The best month was Nov 2023 with a return of +101.9%, while the worst month was Oct 2024 at -47.8%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 4 months.
On a daily basis, TMDX closed higher 49% of trading days. The best single day was Nov 7, 2023 with a return of +51.2%, while the worst single day was Oct 29, 2024 at -29.9%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 10.13% | 8.42% | -31.56% | 1.39% | -33.33% | 12.37% | -37.93% | ||||||
| 2025 | 8.34% | 12.98% | -11.84% | 36.76% | 38.16% | 5.42% | -11.22% | -3.37% | -2.40% | 17.24% | 11.23% | -16.85% | 95.11% |
| 2024 | 8.67% | -4.86% | -9.39% | 27.31% | 44.91% | 10.43% | -5.55% | 18.14% | -6.58% | -47.79% | 5.78% | -28.09% | -21.01% |
| 2023 | 2.11% | 27.05% | -5.42% | 4.45% | -8.14% | 15.58% | 10.95% | -29.57% | -16.58% | -31.54% | 101.92% | 4.29% | 27.88% |
| 2022 | -17.17% | 16.70% | 45.46% | -22.20% | 39.17% | 7.82% | 28.39% | 28.85% | -19.78% | 15.52% | 28.31% | -0.24% | 222.13% |
| 2021 | 14.47% | 57.55% | 15.60% | -30.80% | -10.69% | 29.41% | -14.04% | 14.59% | 1.25% | -17.10% | -19.65% | -13.07% | -3.72% |
Benchmark Metrics
TransMedics Group, Inc. has an annualized alpha of 26.71%, beta of 1.29, and R2 of 0.13 versus S&P 500 Index. Calculated based on daily prices since May 02, 2019.
- This stock captured 192.65% of S&P 500 Index gains and 151.48% of its losses - amplifying both gains and losses, but participating more in upside than downside.
- R2 of 0.13 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 26.71%
- Beta
- 1.29
- R²
- 0.13
- Upside Capture
- 192.65%
- Downside Capture
- 151.48%
Return for Risk
Risk / Return Rank
TMDX ranks 13 for risk / return — in the bottom 13% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for TransMedics Group, Inc. (TMDX) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| TMDX | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.70 | ||
| Sortino ratioReturn per unit of downside risk | -3.51 | ||
| Omega ratioGain probability vs. loss probability | 0.91 | 1.37 | -0.46 |
| Calmar ratioReturn relative to maximum drawdown | -0.66 | 2.78 | -3.45 |
| Martin ratioReturn relative to average drawdown | -1.60 | 12.44 | -14.04 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the TransMedics Group, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the TransMedics Group, Inc. was 73.69%, occurring on Feb 23, 2022. Recovery took 113 trading sessions.
The current TransMedics Group, Inc. drawdown is 57.12%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
Bear market2022 | -73.69%Feb 2022 | 11mo 7d | 5mo 13d | 1y 4moMar 2021 - Aug 2022 |
2025 bear market2025 | -67.79%Jan 2025 | 4mo 26d | — | 1y 9moAug 2024 - now |
COVID crash2020 | -65.47%Mar 2020 | 9mo 28d | 11mo | 1y 8moMay 2019 - Feb 2021 |
2023 bear market2023 | -61.76%Oct 2023 | 3mo 13d | 6mo 2d | 9mo 15dJul 2023 - Apr 2024 |
Bear market2022 | -29.90%Oct 2022 | 1mo 1d | 21d | 1mo 22dSep 2022 - Nov 2022 |
Drawdown Indicators
| TMDX | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -73.69% | -56.78% | -16.91% |
Max Drawdown (1Y)Largest decline over 1 year | -58.76% | -9.10% | -49.66% |
Max Drawdown (3Y)Largest decline over 3 years | -67.79% | -18.90% | -48.89% |
Max Drawdown (5Y)Largest decline over 5 years | -67.79% | -25.43% | -42.36% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -57.12% | -1.80% | -55.32% |
Average DrawdownAverage peak-to-trough decline | -31.96% | -10.71% | -21.25% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 24.32% | 2.03% | +22.29% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of TransMedics Group, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how TransMedics Group, Inc. is priced in the market compared to other companies in the Medical Devices industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for TMDX, comparing it with other companies in the Medical Devices industry. Currently, TMDX has a P/E ratio of 17.4. This P/E ratio is in line with the industry average, suggesting the stock may be fairly valued relative to its earnings.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for TMDX compared to other companies in the Medical Devices industry. TMDX currently has a PEG ratio of 0.0. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for TMDX relative to other companies in the Medical Devices industry. Currently, TMDX has a P/S ratio of 4.7. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for TMDX in comparison with other companies in the Medical Devices industry. Currently, TMDX has a P/B value of 5.5. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with TMDX
Add TransMedics Group, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with TMDX